Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOSon for Previously Untreated Transplant-ineligible Patients With Mantle Cell Lymphoma
NCT07799220Phase 2Not yet recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib, obinutuzumab, sonrotoclax in mantle cell lymphoma (MCL), sponsored by Memorial Sloan Kettering Cancer Center. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
zanubrutinibobinutuzumabsonrotoclax
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT07799220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07799220.